Device Management in HFpEF and HFmrEF: Insights From the REDUCE LAP-HF II Trial

Published: 24 January 2022

  • Views:

    Views Icon 5417
  • Likes:

    Heart Icon 7

Overview

Full programme

  • Views:

    Views Icon 5417
  • Likes:

    Heart Icon 7
Part 2 of 2

Latent Pulmonary Vascular Disease and its Impact on Atrial Shunt Treatment: A Roundtable Discussion

Andrew JS Coats, Barry Borlaug, Gerd Hasenfuß, Sanjiv Shah

Overview

HF with preserved ejection fraction (HFpEF) remains an unmet need, however new therapeutic strategies are emerging to improve quality of life and clinical outcomes. Although medical therapy is the cornerstone of treatment for individuals with EF ≥40%, there is a considerable need for approaches that extend these benefits to individuals who remain symptomatic following medical therapy. 

 

The following videos aim to educate physicians in the changing landscape of the device management of HFpEF.

This programme was supported by an unrestricted educational grant from Corvia Medical

Learning Objectives

  • Explain the clinical rationale behind an atrial shunt in HFpEF
  • Recall overall and pre-specified sub-group results from the REDUCE LAP-HF II trial
  • Describe the clinical features of likely responders and non-responders to an atrial shunt
  • Identify which HFpEF patients are likely to benefit from the use of an atrial shunt
  • Discuss the utility of cardiac interventions for the future treatment of HFpEF

Target Audience

  • Heart Failure Specialists
  • General Cardiologists

More from this programme

Part 1

Data Presentation

Dr Barry Borlaug presents a brief overview of the device and how it gains benefit in HFpEF.

Part 2

Roundtable Discussion

Prof Andrew Coats, Dr Barry Borlaug, Dr Sanjiv Shah and Prof Gerd Hasenfuß review the trial findings and discuss what the data means to the HF community and the wider cardiovascular community, alongside discussing why this data is important.

Faculty Biographies

Andrew JS Coats

Andrew JS Coats

Director of the Monash Warwick Alliance and Academic Vice-President

Personal History6

Professor Andrew Justin Stewart Coats was born in Melbourne, Australia on 1 February 1958. His father was a Professor of Resuscitation who first described essential fatty acids.

He is an Australian-British academic cardiologist as well as a successful fundraiser, university administrator and inventor. 

 

Academic History

Professor Coats attended Melbourne Grammar School and studied at Oxford and Cambridge.9 He has higher doctorates from Oxford (DM) and Imperial (DSc.) and an MBA from London Business School.1 

He obtained a Bachelor of Arts in 1979, a Bachelor of Medicine and Surgery in 1981, a Master of Arts in 1982, a PhD in Management in 1989, became a Doctor of Sciences in 1999 and completed a further Masters in Business Administration in 2001.

He is a Diplomate and Fellow of the

View full profile
Barry Borlaug

Barry Borlaug

View full profile
Gerd Hasenfuß

Gerd Hasenfuß

Professor of Internal Medicine, Director of the Department of Cardiology and Pulmonology

Prof Gerd Hasenfuß is a Professor of Internal Medicine, Director of the Department of Cardiology and Pulmonology, Georg-August-Universität Göttingen; Chairman of the Heart Center and the Herzforschungszentrum Göttingen; Head of Internal Medicine, Clinic and Rehabilitation Center Lippoldsberg gGmbH.

View full profile
Sanjiv Shah

Sanjiv Shah

Professor

Dr Sanjiv Shah’s clinical expertise and research program are focused on HFpEF and in 2007, Dr Shah started the first dedicated HFpEF program in the world at Northwestern University. 

His research, which spans basic research in animal models, clinical physiologic studies, human clinical trials, and population-based epidemiology studies, has highlighted the heterogeneity and systemic nature of the HFpEF syndrome, and has improved the understanding of the risk factors, pathogenesis, and pathophysiology of HFpEF. 

He is an internationally recognised leading authority on HFpEF and routinely lectures at international cardiology meetings, continuing medical education meetings, and academic institutions.

View full profile